MD

Matthew De Silva

COO at Pathos

Chicago, Illinois

Overview

Work Experience

P

Pathos

  • Chief Operating Officer

    2021 - Current

BV

Builders VC

  • Venture Partner

    2021

    Builders VC is an early stage $250M fund based in San Francisco focused on investing where technology meets new business models to modernize antiquated industries. I focus on healthcare and life sciences opportunities for the team. https://www.builders.vc

Longtail Health Ventures

  • Angel Investor & Syndicate Lead

    2021

    Longtail Bio Ventures invests across all stages of development (with a bias for seed/series a) in companies built to exploit the intersection of biology and technology. Apply here: https://angel.co/s/matt-desilva/12QtZ Over the past 7 years I've been a founder in the emerging space of technology companies that focus on applying tech startup playbooks and approaches to company building to biology. My company, Notable, is in the precision medicine oncology field. There any many other startups advancing in a similar way in digital health, drug discovery, genomic and proteomic diagnostics, and clinical trial design, to name a few. Prior to starting Notable I was a portfolio manager at Peter Thiel's family office/hedge fund Clarium Capital. Many of these companies build platform-based technologies, which can be partnered with other larger collaborators and/or used to build out an internal set of products or pipeline. These create exciting long term opportunities for angel investors, because they can reduce the binary aspect of traditional life science investing. I have built up many relationships over the years in this space, so it made sense to begin investing as an angel and leading syndicates. As a CEO I benefitted from AngelList syndicates in several of our financing rounds, so I've been on the other side of the table from syndicate leads. This allows me to tailor my approach to be as founder-friendly as possible. I also believe in syndicates as a tool to bring in value-added angels to companies, so please feel free to reach out to me anytime to see if there are ways you think you can help a portfolio company!

EH

ENDPOINT HEALTH

  • Advisor and Angel Investor

    2020

NL

Notable Labs

  • Founder & Executive Chairman

    2020 - 2023

  • Founder and CEO

    2014 - 2020

CC

Clarium Capital Management

  • Portfolio Manager

    2012 - 2014

Moore Capital Management

  • Intern

    2010 - 2010

Education

Investments

Eigen Therapeutics

Seed

Total Funding: $7M

Arpeggio Bio

Series A

Total Funding: $20M

Enveda Biosciences

Series A

Total Funding: $220M

Relevant Websites